Our Science

We are focused on rapidly designing and developing new medicines based on breakthroughs in cancer research.

OverviewPipeline

Targeting Resistance

Prelude is focused on the rapid design and development of small molecule agents that target known resistance mechanisms. Treatment emergent resistance resulting from primary resistance to the drug targets, acquired resistance through alterations in the same signaling pathway or signaling through alternative pathways that bypass a drug target’s primary mechanism of action are within the scope of Prelude’s research focus.

Our Pipeline

 

Target Compound Indication Discovery Pre-clinical Phase 1 Phase 2
PRMT5
PRT543 Hematological malignancies
Solid tumors

62%

Undisclosed Cancer

52%

Undisclosed Targets
Hematological malignancies

26%

Target Compound Indication Phase
PRMT5
PRT543 Hematological malignancies
Solid tumors
1
Undisclosed Cancer Pre-Clinical
Undisclosed Targets
Hematological malignancies Discovery

Get to know more